BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Instructions to Amplify Certifiable Experience While Chasing after an Internet Advertising Degree - 2Manageable Living: Eco-Accommodating Decisions for Regular day to day existence
- 3Merz visit highlights new strategic, and strained, Germany-Israel bond
- 4The next frontier in space is closer than you think – welcome to the world of very low Earth orbit satellites
- 5Former school bus aide pleads guilty to assaulting 3 autistic students in Colorado
- Which Brilliant Home Gadget Can't You Reside Without?
- Flourishing in a Cutthroat Work Market: Vocation Methodologies
- All the ways Marjorie Taylor Greene has shifted her approach lately — and why Trump is 'surprised at her'
- What we know about the Brown University shooting suspect who was found dead, and how police linked him to the MIT killing
- Doctors thought he had cancer. An offhand suggestion led to a rare diagnosis.
- Two reportedly killed as Israel attacks Hezbollah targets in Lebanon
- They relied on marijuana to get through the day. But then days felt impossible without it
- Overlooked infertility care should be part of national health services, says WHO
- Most loved Occasion Dish: What Makes Your Merry Table?
